Global TMJ Disorders Market By Type (Myofascial Pain, Internal Derangement (ID), Osteoarthritis), By Treatment (Medication, Therapies, Surgical Treatment), By End-User (Hospitals & Clinics, Ambulatory Surgery Centers, Academic Institutes), By Region, and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2021-2031

TMJ disorders, also known as temporomandibular disorders or TMD, are a group of physiological conditions that cause pain and dysfunction in the jaw joints and the muscles that control jaw movement. TMJ disorders afflict approximately 35 million people in the United States, affecting women more than men.

Symptoms of TMJ disorders include pain or tenderness of a jaw, pain in one or both of the temporomandibular joints, aching pain in and around the ear, difficulty in chewing or pain while chewing, aching facial pain, locking of joints thereby making it difficult to open or close one’s mouth. The prevalence of TMJ disorders is estimated to affect more than 5% of the global population.

TMJ disorders are examined from a biopsychosocial or illness perspective, and can be treated by using several treatments. Conservative treatments do not invade the tissues of the face, jaw, or joint, or involve surgery. Reversible treatments do not cause permanent changes in the structure or position of the jaw or teeth. Even when TMJ disorders have become persistent, most patients still do not need aggressive forms of treatment.

Segmentation of Global TMJ Disorders Market

By Type

• Myofascial Pain
• Internal Derangement (ID)
• Osteoarthritis

By Treatment

• Medication
• Therapies
• Surgical Treatment

By End-User

• Hospitals & Clinics
• Ambulatory Surgery Centers
• Academic Institutes
• Other End-Users

By Region

• North America
• Europe
• Asia-Pacific
• South America
• Middle East and Africa

Market Dynamics

The global TMJ disorder industry is expected to register improved market growth due to the increase in technological advancements, as well as the continual increasing prevalence of these disorders. The emergence of non-surgical and surgical treatment methods for TMJ disorders are expected to boost market growth prospects.

TMJ disorders are the second-most commonly occurring musculoskeletal conditions resulting in pain and disability. TMDs are most commonly observed in people between the ages of 20–40 years and occur more often in women than men. Additionally, increased health risks in postmenopausal women such as heart disease and stroke, in which women tend to develop TMD during their premenopausal years, and are more likely to seek treatment for these conditions.

Therefore, the increasing prevalence of these disorders among these populations is expected to further fuel the revenue growth of this global industry in the process.

However, a lack of awareness and low per capita healthcare expenditures among middle and low-income countries may potentially restrain the market growth of this industry over the forecast period.

Competitive Landscape

• Abbott Laboratories
• Sun Pharmaceutical Industries Ltd.
• Bristol Myers Squibb
• Teva Pharmaceutical Industries Ltd.
• Allergan Inc.
• Bayer AG
• Cadila Healthcare Limited
• Novartis International AG
• Pfizer Inc.
• Other Key Players

Recent Developments in this Industry:

• ALLERGAN announced that the company has received approvals from the U.S. Food and Drug Administration (FDA) to market JUVÉDERM VOLLURE XC, for the correction of moderate to severe facial wrinkles and folds, such as nasolabial folds, in adults over the age of 21.
• FDA approved Pfizer’s TROXYCA ER extended-release capsules CII for pain management.

For the TMJ Disorders Market research study, the following years have been considered to estimate the market size: